Withdrawn × Carcinoma, Non-Small-Cell Lung × Carboplatin × Clear all Brigatinib Plus Chemotherapy or Local Consolidation Therapy in ALK Positive Advanced Non-small Cell Lung Cancer (BrightStar-2)
Phase 2 Withdrawn
QUILT-2.024: Phase 2 Neoadjuvant, Consolidation, and Adjuvant Combination NANT Immunotherapy Versus Standard of Care in Subjects With Resectable Non-small Cell Lung Cancer
Phase 2 Withdrawn
Testing the Use of Targeted Treatment for RET Positive Advanced Non-small Cell Lung Cancer
Phase 2 Withdrawn
AdvanTIG-306
Phase 3 Withdrawn
CheckMate 9TN
Phase 2 Withdrawn
A Safety and Feasibility Study of AGS-003-LNG for the Treatment of Stage 3 Non Small Cell Lung Cancer
Phase 2 Withdrawn
A Safety and Tolerability Study of NC318 in Combination With Chemotherapy for Subjects With Advanced or Metastatic NSCLC
Phase 1/2 Withdrawn
CATHAYA
Phase 2 Withdrawn
Hypofractionated Radiotherapy With Carboplatin and Paclitaxel in Non-Small Cell Lung Cancer
Phase 2 Withdrawn
INCMGA00012 in Combination With Chemoradiation in Participants With Stage III Non-Small Cell Lung Cancer (POD1UM-301)
Phase 3 Withdrawn
INCMGA00012 Plus Chemotherapy in Participants With Advanced Solid Tumors (POD1UM-105)
Phase 1 Withdrawn
iTRAP
Phase 1 Withdrawn
Sorafenib and High-Dose Carboplatin, Paclitaxel, and External-Beam Radiation Therapy in Treating Patients With Stage III Non-Small Cell Lung Cancer
Phase 1/2 Withdrawn
Gemcitabine Hydrochloride and Carboplatin With or Without MK-0646 as First-Line Therapy in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer
Phase 2 Withdrawn
Enzastaurin, Carboplatin, and Gemcitabine With or Without Bevacizumab in Treating Patients With Recurrent, Stage IIIB, or Stage IV Non-Small Cell Lung Cancer
Phase 2 Withdrawn
Pemetrexed Disodium and Carboplatin or Cisplatin With or Without Erlotinib Hydrochloride in Treating Patient With Stage IV Non-Small Cell Lung Cancer Resistant to First-Line Therapy With Erlotinib Hydrochloride or Gefitinib
Phase 2 Withdrawn
Sublingual Anvirzel in Advance Non-Small Cell Lung Cancer (NSCLC)
Phase 1 Withdrawn
Abraxane and RT for Non-Small Cell Lung Cancer (NSCLC)
Phase 2 Withdrawn
Phase I IGART Study Using Active Breathing Control and Simultaneous Boost for Patients With NSCLC
Phase 1 Withdrawn
Biomarker-Integrated Approach of Targeted Therapy for Lung Cancer Elimination Plus External Beam Radiation Therapy (BATTLE-XRT)
Phase 1/2 Withdrawn
Afatinib In Combination With Cisplatin Or Carboplatin + Pemetrexed In Patients With EGFR-Mutant Lung Cancers Undergoing Definitive Chemoradiation
Phase 1 Withdrawn
Chemotherapy and Radiation Therapy With or Without Efaproxiral in Treating Patients With Stage III Non-Small Cell Lung Cancer
Phase 3 Withdrawn
Carboplatin, Ixabepilone, and Cetuximab in Patients With Stage III or Stage IV Non-Small Cell Lung Cancer Previously Untreated With Chemotherapy
Phase 2 Withdrawn
Study to Assess Safety and Tolerability of AZD0530 in Combination With Carboplatin and Paclitaxel
Phase 1 Withdrawn
27 enrolled